Analysis of human tumor immune infiltrate suggests that the presence of CD8+ T cells in the tumor microenvironment (TME) correlates with improved disease outcomes and has positioned CD8+ T cells as a central mainstay of immunotherapeutic strategies [9]. The gene discussed is CD8A; the disease is neoplasm.